Kaken Pharmaceutical（4521）株式概要科研製薬株式会社は、医療用医薬品、医療機器、農薬の製造・販売および国内外への販売を行っている。 詳細4521 ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績0/6財務の健全性5/6配当金5/6報酬当社が推定した公正価値より31.1%で取引されている リスク分析今後3年間の収益は年平均15.9%減少すると予測されている。 財務結果に影響を与える大きな一時的項目 4.71%の配当はフリーキャッシュフローで十分にカバーされていない すべてのリスクチェックを見る4521 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW482,187 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA482,187 investors already sharing narrativesYour Fair ValueJP¥Current PriceJP¥4.03k35.6% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture0108b2016201920222025202620282031Revenue JP¥83.0bEarnings JP¥9.7bAdvancedSet Fair ValueView all narrativesKaken Pharmaceutical Co., Ltd. 競合他社Towa PharmaceuticalSymbol: TSE:4553Market cap: JP¥188.5bKissei PharmaceuticalSymbol: TSE:4547Market cap: JP¥170.4bSawai Group HoldingsSymbol: TSE:4887Market cap: JP¥185.4bMochida PharmaceuticalSymbol: TSE:4534Market cap: JP¥113.8b価格と性能株価の高値、安値、推移の概要Kaken Pharmaceutical過去の株価現在の株価JP¥4,030.0052週高値JP¥4,445.0052週安値JP¥3,540.00ベータ01ヶ月の変化4.40%3ヶ月変化-3.01%1年変化2.49%3年間の変化13.30%5年間の変化-22.94%IPOからの変化67.92%最新ニュースReported Earnings • Aug 08First quarter 2027 earnings released: EPS: JP¥223 (vs JP¥7.12 in 1Q 2026)First quarter 2027 results: EPS: JP¥223 (up from JP¥7.12 in 1Q 2026). Revenue: JP¥30.2b (up 60% from 1Q 2026). Net income: JP¥8.44b (up JP¥8.17b from 1Q 2026). Profit margin: 28% (up from 1.4% in 1Q 2026). Revenue is expected to decline by 1.2% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 3.4%. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.Declared Dividend • Jul 25Final dividend of JP¥95.00 announcedShareholders will receive a dividend of JP¥95.00. Ex-date: 29th September 2026 Payment date: 30th November 2026 Dividend yield will be 4.9%, which is higher than the industry average of 2.3%. Sustainability & Growth Dividend is not covered by earnings (336% earnings payout ratio) and the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 3.4% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 273% to bring the payout ratio under control. EPS is expected to grow by 33% over the next 3 years, which means the dividend may need to be reduced to reach a sustainable payout ratio.Major Estimate Revision • Jul 22Consensus EPS estimates increase by 44%The consensus outlook for earnings per share (EPS) in fiscal year 2027 has improved. 2027 revenue forecast increased from JP¥79.6b to JP¥82.8b. EPS estimate increased from JP¥85.09 to JP¥122 per share. Net income forecast to grow 116% next year vs 3.4% growth forecast for Pharmaceuticals industry in Japan. Consensus price target up from JP¥4,350 to JP¥4,500. Share price was steady at JP¥3,890 over the past week.Buy Or Sell Opportunity • Jun 26Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to JP¥3,815. The fair value is estimated to be JP¥4,804, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Earnings per share has declined by 6.4%. For the next 3 years, revenue is forecast to grow by 2.2% per annum. Earnings are also forecast to grow by 15% per annum over the same time period.Major Estimate Revision • Jun 17Consensus EPS estimates increase by 54%The consensus outlook for earnings per share (EPS) in fiscal year 2027 has improved. 2027 revenue forecast increased from JP¥76.5b to JP¥79.6b. EPS estimate increased from JP¥55.42 to JP¥85.09 per share. Net income forecast to grow 50% next year vs 3.3% growth forecast for Pharmaceuticals industry in Japan. Consensus price target broadly unchanged at JP¥4,350. Share price was steady at JP¥3,830 over the past week.Buy Or Sell Opportunity • Jun 02Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to JP¥3,790. The fair value is estimated to be JP¥4,804, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Earnings per share has declined by 6.4%. For the next 3 years, revenue is forecast to grow by 2.4% per annum. Earnings are also forecast to grow by 20% per annum over the same time period.最新情報をもっと見るRecent updatesReported Earnings • Aug 08First quarter 2027 earnings released: EPS: JP¥223 (vs JP¥7.12 in 1Q 2026)First quarter 2027 results: EPS: JP¥223 (up from JP¥7.12 in 1Q 2026). Revenue: JP¥30.2b (up 60% from 1Q 2026). Net income: JP¥8.44b (up JP¥8.17b from 1Q 2026). Profit margin: 28% (up from 1.4% in 1Q 2026). Revenue is expected to decline by 1.2% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 3.4%. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.Declared Dividend • Jul 25Final dividend of JP¥95.00 announcedShareholders will receive a dividend of JP¥95.00. Ex-date: 29th September 2026 Payment date: 30th November 2026 Dividend yield will be 4.9%, which is higher than the industry average of 2.3%. Sustainability & Growth Dividend is not covered by earnings (336% earnings payout ratio) and the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 3.4% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 273% to bring the payout ratio under control. EPS is expected to grow by 33% over the next 3 years, which means the dividend may need to be reduced to reach a sustainable payout ratio.Major Estimate Revision • Jul 22Consensus EPS estimates increase by 44%The consensus outlook for earnings per share (EPS) in fiscal year 2027 has improved. 2027 revenue forecast increased from JP¥79.6b to JP¥82.8b. EPS estimate increased from JP¥85.09 to JP¥122 per share. Net income forecast to grow 116% next year vs 3.4% growth forecast for Pharmaceuticals industry in Japan. Consensus price target up from JP¥4,350 to JP¥4,500. Share price was steady at JP¥3,890 over the past week.Buy Or Sell Opportunity • Jun 26Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to JP¥3,815. The fair value is estimated to be JP¥4,804, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Earnings per share has declined by 6.4%. For the next 3 years, revenue is forecast to grow by 2.2% per annum. Earnings are also forecast to grow by 15% per annum over the same time period.Major Estimate Revision • Jun 17Consensus EPS estimates increase by 54%The consensus outlook for earnings per share (EPS) in fiscal year 2027 has improved. 2027 revenue forecast increased from JP¥76.5b to JP¥79.6b. EPS estimate increased from JP¥55.42 to JP¥85.09 per share. Net income forecast to grow 50% next year vs 3.3% growth forecast for Pharmaceuticals industry in Japan. Consensus price target broadly unchanged at JP¥4,350. Share price was steady at JP¥3,830 over the past week.Buy Or Sell Opportunity • Jun 02Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to JP¥3,790. The fair value is estimated to be JP¥4,804, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Earnings per share has declined by 6.4%. For the next 3 years, revenue is forecast to grow by 2.4% per annum. Earnings are also forecast to grow by 20% per annum over the same time period.お知らせ • May 30Kaken Pharmaceutical Co., Ltd. to Report Q1, 2027 Results on Aug 07, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2027 results on Aug 07, 2026分析記事 • May 20Why Kaken Pharmaceutical's (TSE:4521) Shaky Earnings Are Just The Beginning Of Its ProblemsKaken Pharmaceutical Co., Ltd.'s ( TSE:4521 ) recent weak earnings report didn't cause a big stock movement. We think...Reported Earnings • May 15Full year 2026 earnings: EPS in line with analyst expectations despite revenue beatFull year 2026 results: EPS: JP¥56.55 (down from JP¥365 in FY 2025). Revenue: JP¥76.9b (down 18% from FY 2025). Net income: JP¥2.14b (down 85% from FY 2025). Profit margin: 2.8% (down from 15% in FY 2025). Revenue exceeded analyst estimates by 5.5%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.お知らせ • May 13Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2026Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2026.お知らせ • Apr 01Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 13, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 13, 2026Upcoming Dividend • Mar 23Upcoming dividend of JP¥95.00 per shareEligible shareholders must have bought the stock before 30 March 2026. Payment date: 30 June 2026. The company is not currently making a profit and is not cash flow positive. Trailing yield: 4.6%. Within top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (2.4%).Reported Earnings • Feb 07Third quarter 2026 earnings: EPS and revenues miss analyst expectationsThird quarter 2026 results: EPS: JP¥10.72 (down from JP¥129 in 3Q 2025). Revenue: JP¥18.3b (down 26% from 3Q 2025). Net income: JP¥406.0m (down 92% from 3Q 2025). Profit margin: 2.2% (down from 20% in 3Q 2025). Revenue missed analyst estimates by 5.7%. Earnings per share (EPS) also missed analyst estimates by 57%. Revenue is expected to decline by 2.0% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 3.9%. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 5% per year.分析記事 • Dec 19Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥95.00Kaken Pharmaceutical Co., Ltd.'s ( TSE:4521 ) investors are due to receive a payment of ¥95.00 per share on 30th of...お知らせ • Dec 19Kaken Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 06, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026分析記事 • Nov 29Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥95.00Kaken Pharmaceutical Co., Ltd. ( TSE:4521 ) will pay a dividend of ¥95.00 on the 30th of June. This takes the dividend...Declared Dividend • Nov 29First half dividend of JP¥95.00 announcedShareholders will receive a dividend of JP¥95.00. Ex-date: 30th March 2026 Payment date: 30th June 2026 Dividend yield will be 4.9%, which is higher than the industry average of 2.3%. Sustainability & Growth Dividend is not covered by earnings (440% earnings payout ratio) and the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 5.8% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 389% to bring the payout ratio under control. EPS is expected to grow by 34% over the next 3 years, which means the dividend may need to be reduced to reach a sustainable payout ratio.分析記事 • Nov 18We Think You Can Look Beyond Kaken Pharmaceutical's (TSE:4521) Lackluster EarningsShareholders appeared unconcerned with Kaken Pharmaceutical Co., Ltd.'s ( TSE:4521 ) lackluster earnings report last...Reported Earnings • Nov 12Second quarter 2026 earnings released: EPS: JP¥19.04 (vs JP¥331 in 2Q 2025)Second quarter 2026 results: EPS: JP¥19.04 (down from JP¥331 in 2Q 2025). Revenue: JP¥20.5b (down 38% from 2Q 2025). Net income: JP¥721.0m (down 94% from 2Q 2025). Profit margin: 3.5% (down from 38% in 2Q 2025). Revenue is expected to decline by 3.6% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 3.8%. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.お知らせ • Sep 29Kaken Pharmaceutical Co., Ltd. Revises Consolidated Financial Forecast for Fiscal Year Ending March 31, 2026Kaken Pharmaceutical Co., Ltd. revised consolidated financial forecast for fiscal year ending March 31, 2026. For the period, the company expects net sales of JPY 86,300 million compared to previous guidance of JPY 88,000 million, operating profit of JPY 2,100 million compared to previous guidance of JPY 5,200 million and profit attributable to owners of parent company of JPY 2,300 compared to previous guidance of JPY 3,400 million or basic earnings per share of JPY 60.74 per share compared to previous guidance of JPY 88.53.Upcoming Dividend • Sep 22Upcoming dividend of JP¥95.00 per shareEligible shareholders must have bought the stock before 29 September 2025. Payment date: 01 December 2025. Payout ratio is a comfortable 46% and this is well supported by cash flows. Trailing yield: 4.9%. Within top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (2.7%).お知らせ • Sep 11Kaken Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 10, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 10, 2025Reported Earnings • Aug 08First quarter 2026 earnings released: EPS: JP¥7.12 (vs JP¥46.32 in 1Q 2025)First quarter 2026 results: EPS: JP¥7.12 (down from JP¥46.32 in 1Q 2025). Revenue: JP¥18.9b (up 3.4% from 1Q 2025). Net income: JP¥271.0m (down 85% from 1Q 2025). Profit margin: 1.4% (down from 9.6% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is expected to decline by 6.3% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 3.9%. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Declared Dividend • Jul 09Final dividend of JP¥95.00 announcedShareholders will receive a dividend of JP¥95.00. Ex-date: 29th September 2025 Payment date: 1st December 2025 Dividend yield will be 4.5%, which is higher than the industry average of 2.3%. Sustainability & Growth Dividend is well covered by both earnings (28% earnings payout ratio) and cash flows (28% cash payout ratio). The dividend has increased by an average of 5.8% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to decline by 83% over the next 3 years. Since a fall of 69% would increase the payout ratio to a potentially unsustainable range, the dividend may be at risk.お知らせ • May 31Kaken Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025Major Estimate Revision • May 29Consensus revenue estimates increase by 19%, EPS downgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from JP¥74.2b to JP¥88.3b. EPS estimate fell from JP¥128 to JP¥80.45. Net income forecast to shrink 78% next year vs 0.2% growth forecast for Pharmaceuticals industry in Japan . Consensus price target down from JP¥4,850 to JP¥4,600. Share price rose 2.0% to JP¥3,813 over the past week.分析記事 • May 19We Think Kaken Pharmaceutical's (TSE:4521) Robust Earnings Are ConservativeInvestors were underwhelmed by the solid earnings posted by Kaken Pharmaceutical Co., Ltd. ( TSE:4521 ) recently. We...Reported Earnings • May 13Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: EPS: JP¥365 (up from JP¥213 in FY 2024). Revenue: JP¥94.0b (up 31% from FY 2024). Net income: JP¥13.9b (up 74% from FY 2024). Profit margin: 15% (up from 11% in FY 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 3.8%. Earnings per share (EPS) missed analyst estimates by 6.5%. Revenue is expected to decline by 8.0% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 3.6%. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.分析記事 • May 12We Think Kaken Pharmaceutical (TSE:4521) Can Manage Its Debt With EaseWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...お知らせ • May 12+ 3 more updatesKaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2025Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2025.分析記事 • Apr 15There's Reason For Concern Over Kaken Pharmaceutical Co., Ltd.'s (TSE:4521) PriceWith a median price-to-sales (or "P/S") ratio of close to 1.5x in the Pharmaceuticals industry in Japan, you could be...お知らせ • Apr 11Kaken Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecast for Fiscal Year Ended March 31, 2025Kaken Pharmaceutical Co., Ltd. revised consolidated earnings forecast for fiscal year ended March 31, 2025. For the year, the company expected net sales of JPY 94,000 million compared to previous forecast of JPY 88,500 million; Operating profit of JPY 20,800 million compared to previous forecast of JPY 20,800 million; Profit attributable to owners of the parent of JPY 14,000 million compared to previous forecast of JPY 14,200 million and Basic earnings per share of JPY 364.55 compared to previous forecast of JPY 374.97. The forecast for net sales has been revised upward from the previously announced forecast to reflect the receipt of an upfront payment as described in the press release KAKEN Entered into a License Agreement for STAT6 Inhibitor announced on December 26, 2024, and other factors. Operating profit, ordinary profit, and profit attributable to owners of the parent have been partially revised to reflect the upfront payment as described in the press release Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan announced on March 25, 2025, as well as the expenses described in the press release Notice of Completion of Acquisition of Aadi Subsidiaries, Inc, U.S.A. announced on March 27, 2025.分析記事 • Mar 27Kaken Pharmaceutical (TSE:4521) Is Due To Pay A Dividend Of ¥75.00Kaken Pharmaceutical Co., Ltd. ( TSE:4521 ) will pay a dividend of ¥75.00 on the 30th of June. This means the annual...お知らせ • Mar 26Kaken Pharmaceutical Co., Ltd. (TSE:4521) completed the acquisition of Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $102.4 million.Kaken Pharmaceutical Co., Ltd. (TSE:4521) entered into a stock purchase agreement to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million on December 19, 2024. The purchase price is subject to customary adjustments. The board of directors of Aadi approved and recommend that Aadi’s stockholders vote in favor of, and authorize the approval of, the purchase agreement and stock purchase. Completion of the stock purchase is subject to customary closing conditions, including all consents and approvals required under certain regulatory laws having been obtained and the absence of any law or order preventing, materially restraining or materially impairing the consummation of the stock purchase. Completion of the Stock Purchase is also subject, with certain exception, to the completion of certain internal pre-closing restructuring transaction. In case of termination of transaction, Aadi Bioscience, Inc. will pay a termination fee of $3.50 million. The transaction is expected to close in the first half of 2025. On February 28, 2025, shareholders of Aadi Bioscience approved the transaction. Matt Carter and David A. Lipkin of McDermott Will & Emery LLP acted as legal advisor to Kaken Pharmaceutical Co., Ltd. Dan Koeppen, Robert L. Wernli, Jr., Ethan Lutske and Jack Hamilton of Wilson Sonsini Goodrich & Rosati acted as legal advisor and Leerink Partners LLC acted as Financial advisor to Aadi Bioscience, Inc. Kaken Pharmaceutical Co., Ltd. (TSE:4521) completed the acquisition of Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $102.4 million on March 25, 2025.お知らせ • Mar 25Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 12, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 12, 2025Upcoming Dividend • Mar 21Upcoming dividend of JP¥75.00 per shareEligible shareholders must have bought the stock before 28 March 2025. Payment date: 30 June 2025. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 3.2%. Lower than top quartile of Japanese dividend payers (3.7%). Higher than average of industry peers (2.6%).分析記事 • Mar 13Kaken Pharmaceutical (TSE:4521) Will Pay A Dividend Of ¥75.00Kaken Pharmaceutical Co., Ltd. ( TSE:4521 ) has announced that it will pay a dividend of ¥75.00 per share on the 30th...分析記事 • Feb 27Kaken Pharmaceutical (TSE:4521) Has Affirmed Its Dividend Of ¥75.00Kaken Pharmaceutical Co., Ltd. ( TSE:4521 ) has announced that it will pay a dividend of ¥75.00 per share on the 30th...お知らせ • Feb 26Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces an Equity Buyback for 1,800,000 shares, representing 4.53% for ¥9,000 million.Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces a share repurchase program. Under the program, the company will repurchase 1,800,000 shares, representing 4.53% of its share capital, for ¥9,000 million. The purpose of the program is to strengthen shareholder returns and improve capital efficiency, as well as to address the dilution of shares resulting from the disposal of treasury stock. The program will run until September 30, 2025. As of January 31, 2025, the company had 39,758,792 shares in issue (excluding treasury stock) and 6,180,938 shares of treasury stock.分析記事 • Feb 10Kaken Pharmaceutical (TSE:4521) Is Due To Pay A Dividend Of ¥75.00The board of Kaken Pharmaceutical Co., Ltd. ( TSE:4521 ) has announced that it will pay a dividend on the 30th of June...Reported Earnings • Feb 07Third quarter 2025 earnings released: EPS: JP¥129 (vs JP¥68.84 in 3Q 2024)Third quarter 2025 results: EPS: JP¥129 (up from JP¥68.84 in 3Q 2024). Revenue: JP¥24.6b (up 33% from 3Q 2024). Net income: JP¥4.89b (up 88% from 3Q 2024). Profit margin: 20% (up from 14% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is expected to decline by 10% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 4.2%. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.分析記事 • Jan 10Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00Kaken Pharmaceutical Co., Ltd. ( TSE:4521 ) will pay a dividend of ¥75.00 on the 30th of June. The dividend yield will...お知らせ • Dec 22Kaken Pharmaceutical Co., Ltd. (TSE:4521) agreed to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million.Kaken Pharmaceutical Co., Ltd. (TSE:4521) agreed to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million on December 19, 2024. Completion of the Stock Purchase is subject to customary closing conditions, including the approval of the Purchase Agreement and the Stock Purchase by the holders of a majority of the outstanding shares of Aadi’s capital stock entitled to vote to approve the Purchase Agreement and Stock Purchase, all consents and approvals required under certain regulatory laws having been obtained and the absence of any law or order preventing, materially restraining or materially impairing the consummation of the Stock Purchase. Completion of the Stock Purchase is also subject, with certain exception, to the completion of certain internal pre-closing restructuring transaction. In case of termination of transaction, Aadi Bioscience, Inc. will pay a termination fee of $3.50 million. The transaction is expected to close in the first half of 2025. Matt Carter and David A. Lipkin of McDermott Will & Emery LLP acted as legal advisor to Kaken Pharmaceutical Co., Ltd. Dan Koeppen, Robert L. Wernli, Jr., Ethan Lutske and Jack Hamilton of Wilson Sonsini Goodrich & Rosati acted as legal advisor to分析記事 • Dec 20Kaken Pharmaceutical (TSE:4521) Has Announced A Dividend Of ¥75.00The board of Kaken Pharmaceutical Co., Ltd. ( TSE:4521 ) has announced that it will pay a dividend of ¥75.00 per share...分析記事 • Dec 02Kaken Pharmaceutical (TSE:4521) Will Pay A Dividend Of ¥75.00Kaken Pharmaceutical Co., Ltd.'s ( TSE:4521 ) investors are due to receive a payment of ¥75.00 per share on 30th of...Declared Dividend • Nov 30First half dividend of JP¥75.00 announcedShareholders will receive a dividend of JP¥75.00. Ex-date: 28th March 2025 Payment date: 30th June 2025 Dividend yield will be 4.4%, which is higher than the industry average of 2.3%. Sustainability & Growth Dividend is well covered by both earnings (31% earnings payout ratio) and cash flows (24% cash payout ratio). The dividend has increased by an average of 4.6% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to decline by 92% over the next 3 years. Since a fall of 65% would increase the payout ratio to a potentially unsustainable range, the dividend may be at risk.お知らせ • Nov 30Kaken Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 06, 2025Major Estimate Revision • Nov 15Consensus EPS estimates increase by 10%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from JP¥83.1b to JP¥87.8b. EPS estimate increased from JP¥354 to JP¥391 per share. Net income forecast to shrink 50% next year vs 0.4% decline forecast for Pharmaceuticals industry in Japan. Consensus price target of JP¥3,600 unchanged from last update. Share price rose 13% to JP¥4,369 over the past week.Reported Earnings • Nov 09Second quarter 2025 earnings released: EPS: JP¥331 (vs JP¥41.29 in 2Q 2024)Second quarter 2025 results: EPS: JP¥331 (up from JP¥41.29 in 2Q 2024). Revenue: JP¥33.1b (up 84% from 2Q 2024). Net income: JP¥12.5b (up JP¥11.0b from 2Q 2024). Profit margin: 38% (up from 8.6% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is expected to decline by 8.9% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 4.5%. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 3% per year.Upcoming Dividend • Sep 20Upcoming dividend of JP¥115 per shareEligible shareholders must have bought the stock before 27 September 2024. Payment date: 02 December 2024. Payout ratio is on the higher end at 78%, and the cash payout ratio is above 100%. Trailing yield: 3.8%. Within top quartile of Japanese dividend payers (3.8%). Higher than average of industry peers (2.3%).お知らせ • Sep 03Kaken Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 08, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 08, 2024分析記事 • Aug 13Estimating The Intrinsic Value Of Kaken Pharmaceutical Co., Ltd. (TSE:4521)Key Insights Using the Dividend Discount Model, Kaken Pharmaceutical fair value estimate is JP¥3,765 Current share...分析記事 • Jul 26Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00Kaken Pharmaceutical Co., Ltd. ( TSE:4521 ) will pay a dividend of ¥75.00 on the 2nd of December. This makes the...Major Estimate Revision • Jul 12Consensus revenue estimates increase by 18%The consensus outlook for revenues in fiscal year 2025 has improved. 2025 revenue forecast increased from JP¥70.2b to JP¥83.1b. EPS estimate increased from JP¥172 to JP¥354 per share. Net income forecast to grow 67% next year vs 0.1% decline forecast for Pharmaceuticals industry in Japan. Consensus price target up from JP¥3,500 to JP¥3,600. Share price rose 3.3% to JP¥4,058 over the past week.分析記事 • Jul 11Kaken Pharmaceutical (TSE:4521) Has Announced A Dividend Of ¥75.00Kaken Pharmaceutical Co., Ltd. ( TSE:4521 ) will pay a dividend of ¥75.00 on the 2nd of December. This makes the...Buy Or Sell Opportunity • Jul 11Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 17% to JP¥4,012. The fair value is estimated to be JP¥3,330, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 37%. For the next 3 years, revenue is forecast to decline by 6.5% per annum. Earnings are also forecast to decline by 48% per annum over the same time period.お知らせ • Jun 26Kaken Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 07, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Aug 07, 2024Reported Earnings • May 16Full year 2024 earnings: EPS exceeds analyst expectationsFull year 2024 results: EPS: JP¥213 (up from JP¥145 in FY 2023). Revenue: JP¥72.0b (down 1.3% from FY 2023). Net income: JP¥8.03b (up 48% from FY 2023). Profit margin: 11% (up from 7.5% in FY 2023). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 7.5%. Revenue is expected to decline by 6.5% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 4.5%. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.お知らせ • May 16Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024.Upcoming Dividend • Mar 21Upcoming dividend of JP¥75.00 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 01 July 2024. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 4.2%. Within top quartile of Japanese dividend payers (3.2%). Higher than average of industry peers (2.3%).分析記事 • Mar 04Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00Kaken Pharmaceutical Co., Ltd. ( TSE:4521 ) will pay a dividend of ¥75.00 on the 1st of July. This means the annual...お知らせ • Mar 03Kaken Pharmaceutical Co., Ltd. to Report Q4, 2024 Results on May 09, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q4, 2024 results on May 09, 2024Reported Earnings • Feb 08Third quarter 2024 earnings released: EPS: JP¥68.84 (vs JP¥85.00 in 3Q 2023)Third quarter 2024 results: EPS: JP¥68.84 (down from JP¥85.00 in 3Q 2023). Revenue: JP¥18.5b (down 1.3% from 3Q 2023). Net income: JP¥2.61b (down 18% from 3Q 2023). Profit margin: 14% (down from 17% in 3Q 2023). Revenue is expected to decline by 6.1% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 4.6%. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.お知らせ • Dec 08Kaken Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 06, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Feb 06, 2024お知らせ • Nov 15+ 1 more updateKaken Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for Fiscal Year Ending March 31, 2024Kaken Pharmaceutical Co., Ltd. provided consolidated financial forecast for fiscal year ending March 31, 2024. For the year, the company expects net sales of ¥73,100 million, operating profit of ¥7,600 million, profit attributable to owners of the company of ¥6,700 million and basic earnings per share of ¥176.92.Reported Earnings • Nov 10Second quarter 2024 earnings released: EPS: JP¥41.28 (vs JP¥81.46 in 2Q 2023)Second quarter 2024 results: EPS: JP¥41.28 (down from JP¥81.46 in 2Q 2023). Revenue: JP¥18.0b (down 3.2% from 2Q 2023). Net income: JP¥1.56b (down 49% from 2Q 2023). Profit margin: 8.6% (down from 16% in 2Q 2023). Revenue is expected to decline by 5.9% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 3.5%. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Sep 21Upcoming dividend of JP¥75.00 per share at 4.2% yieldEligible shareholders must have bought the stock before 28 September 2023. Payment date: 30 November 2023. The company is paying out more than 100% of its profits and is paying out 80% of its cash flow. Trailing yield: 4.2%. Within top quartile of Japanese dividend payers (3.3%). Higher than average of industry peers (2.2%).お知らせ • Sep 19Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index (USD)Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index (USD)お知らせ • Aug 30Kaken Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 08, 2023Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2024 results on Nov 08, 2023お知らせ • Aug 18+ 1 more updateKaken Pharmaceutical Co., Ltd. Provides Dividend Forecast for Second Quarter of 2024 and Fiscal Year Ending March 31, 2024Kaken Pharmaceutical Co., Ltd. provided dividend forecast for second quarter of 2024 and fiscal year ending March 31, 2024. For the quarter, the company expects to pay a dividend of ¥75 against ¥75 paid last year.For the year, the company expects to pay a dividend of ¥75 against ¥75 paid last year.Reported Earnings • Aug 09First quarter 2024 earnings released: EPS: JP¥66.98 (vs JP¥76.89 in 1Q 2023)First quarter 2024 results: EPS: JP¥66.98 (down from JP¥76.89 in 1Q 2023). Revenue: JP¥18.2b (flat on 1Q 2023). Net income: JP¥2.51b (down 14% from 1Q 2023). Profit margin: 14% (down from 16% in 1Q 2023). Revenue is expected to decline by 5.7% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 3.9%. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.New Risk • Jul 16New minor risk - Dividend sustainabilityThe dividend is not well covered by earnings. Payout ratio: 104% Dividend yield: 4.3% This is considered a minor risk. Companies that pay out too much of their earnings are at risk of having to reduce or cut their dividend in future. If earnings growth slows or earnings fall, then there may not be enough earnings to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. However, this risk is mitigated by the fact the dividend is covered by cash flows. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 30% per year for the foreseeable future. Minor Risks Dividend is not well covered by earnings (104% payout ratio). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (7.5% net profit margin).Major Estimate Revision • Jun 03Consensus EPS estimates fall by 26%, revenue upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from JP¥69.6b to JP¥72.7b. EPS estimate fell from JP¥267 to JP¥198 per share. Net income forecast to grow 40% next year vs 9.7% growth forecast for Pharmaceuticals industry in Japan. Consensus price target up from JP¥3,200 to JP¥3,500. Share price was steady at JP¥3,585 over the past week.お知らせ • May 28Kaken Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 04, 2023Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Aug 04, 2023お知らせ • May 12Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023.Reported Earnings • May 12Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2023 results: EPS: JP¥145 (down from JP¥251 in FY 2022). Revenue: JP¥73.0b (down 4.0% from FY 2022). Net income: JP¥5.44b (down 43% from FY 2022). Profit margin: 7.5% (down from 13% in FY 2022). Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) missed analyst estimates by 50%. Revenue is expected to decline by 6.5% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 4.6%. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Mar 23Upcoming dividend of JP¥75.00 per share at 4.1% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 30 June 2023. Payout ratio is a comfortable 67% and this is well supported by cash flows. Trailing yield: 4.1%. Within top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (2.3%).Reported Earnings • Feb 04Third quarter 2023 earnings released: EPS: JP¥84.99 (vs JP¥93.21 in 3Q 2022)Third quarter 2023 results: EPS: JP¥84.99 (down from JP¥93.21 in 3Q 2022). Revenue: JP¥18.8b (down 6.8% from 3Q 2022). Net income: JP¥3.19b (down 9.6% from 3Q 2022). Profit margin: 17% (in line with 3Q 2022). Revenue is expected to decline by 6.0% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 4.8%. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.お知らせ • Dec 28Kaken Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 03, 2023Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Feb 03, 2023Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: JP¥81.46 (vs JP¥88.47 in 2Q 2022)Second quarter 2023 results: EPS: JP¥81.46 (down from JP¥88.47 in 2Q 2022). Revenue: JP¥18.6b (down 2.7% from 2Q 2022). Net income: JP¥3.06b (down 9.0% from 2Q 2022). Profit margin: 16% (down from 18% in 2Q 2022). Revenue is expected to decline by 6.0% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 4.5%. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 2 independent directors. 7 non-independent directors. Independent Outside Director Shoichiro Takagi was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Reported Earnings • Nov 10Second quarter 2023 earnings released: EPS: JP¥81.46 (vs JP¥88.47 in 2Q 2022)Second quarter 2023 results: EPS: JP¥81.46 (down from JP¥88.47 in 2Q 2022). Revenue: JP¥18.6b (down 2.7% from 2Q 2022). Net income: JP¥3.06b (down 9.0% from 2Q 2022). Profit margin: 16% (down from 18% in 2Q 2022). Revenue is expected to decline by 6.0% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 4.6%. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Sep 22Upcoming dividend of JP¥75.00 per shareEligible shareholders must have bought the stock before 29 September 2022. Payment date: 30 November 2022. Payout ratio is a comfortable 62% and this is well supported by cash flows. Trailing yield: 4.0%. Within top quartile of Japanese dividend payers (3.7%). Higher than average of industry peers (2.3%).お知らせ • Aug 28Kaken Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Nov 08, 2022Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2023 results on Nov 08, 2022Reported Earnings • Aug 04First quarter 2023 earnings released: EPS: JP¥76.89 (vs JP¥87.76 in 1Q 2022)First quarter 2023 results: EPS: JP¥76.89 (down from JP¥87.76 in 1Q 2022). Revenue: JP¥18.2b (down 1.4% from 1Q 2022). Net income: JP¥2.91b (down 14% from 1Q 2022). Profit margin: 16% (down from 18% in 1Q 2022). Over the next year, revenue is expected to shrink by 6.3% compared to a 4.7% growth forecast for the industry in Japan. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.お知らせ • Jun 03Kaken Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 03, 2022Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2023 results on Aug 03, 2022お知らせ • May 26+ 1 more updateKaken Pharmaceutical Co., Ltd. Announces Year-End Dividend for the Fiscal Year Ended March 31, 2022, Payable on June 30, 2022; Provides Second Quarter and Fiscal Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2023Kaken Pharmaceutical Co., Ltd. announced year end dividend of JPY 75 per share for the fiscal year ended March 31, 2022, payable on June 30, 2022, compared to JPY 75 per share paid an year ago.Kaken Pharmaceutical Co., Ltd. provided second quarter and fiscal year ending March 31, 2023 dividend guidance of JPY 75 per share each, compared to JPY 75 per share paid during fiscal year ended March 31, 2022.Reported Earnings • May 13Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: EPS: JP¥251 (down from JP¥347 in FY 2021). Revenue: JP¥76.0b (up 1.4% from FY 2021). Net income: JP¥9.55b (down 29% from FY 2021). Profit margin: 13% (down from 18% in FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.4%. Over the next year, revenue is expected to shrink by 6.6% compared to a 4.6% growth forecast for the pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.お知らせ • May 13Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2022Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2022.お知らせ • May 12Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces an Equity Buyback for 350,000 shares, representing 0.92% for ¥1,500 million.Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces a share repurchase program. Under the program, the company will repurchase 350,000 shares, representing 0.92% of its share capital, for ¥1,500 million. The purpose of the program is to implement a flexible capital policy in response to changes in the business environment. The program will run until December 28, 2022. As of April 30, 2022, the company had 37,856,819 shares in issue (excluding treasury stock) and 8,082,911 shares of treasury stock.株主還元4521JP PharmaceuticalsJP 市場7D0.7%-1.7%1.2%1Y2.5%9.1%32.0%株主還元を見る業界別リターン: 4521過去 1 年間で9.1 % の収益を上げたJP Pharmaceuticals業界を下回りました。リターン対市場: 4521は、過去 1 年間で32 % のリターンを上げたJP市場を下回りました。価格変動Is 4521's price volatile compared to industry and market?4521 volatility4521 Average Weekly Movement2.5%Pharmaceuticals Industry Average Movement4.3%Market Average Movement4.1%10% most volatile stocks in JP Market9.0%10% least volatile stocks in JP Market2.1%安定した株価: 4521 、 JP市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 4521の 週次ボラティリティ ( 3% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19171,114Hiroyuki Horiuchiwww.kaken.co.jp科研製薬(株)は、医療用医薬品、医療機器、農薬の製造・販売および国内外への販売を行っている。爪白癬外用剤「クレナフィン」、抗骨関節炎剤「アートス」、創傷治癒剤「フィブラスト」、原発性腋窩多汗症治療剤「エクロック」、歯周病再生剤「レグロス」、腰椎椎間板ヘルニア治療剤「ヘルニコール」、主に外科や婦人科で使用され、術後の癒着による合併症を軽減する癒着防止剤「セプラフィルム」などの医薬品や医療機器を提供している。また、殺菌剤として使用されるポリオキシン、稲用除草剤ペントキサゾンおよびメタミホップ、鶏用抗コクシジウム飼料添加物サリノマイシン、牛用尿石溶解・排泄促進剤ウロストンなどの農薬および動物用医薬品も提供している。さらに、エスチャーの除去剤KMW-1、アタマジラミの治療薬として第III相臨床試験中のKAR、難治性血管奇形の治療薬として第III相臨床試験中のKP-001、原発性胆汁性胆管炎の治療薬として第III相臨床試験中のSeladelparを開発している；固形がんを対象とした第I相臨床試験中のKP-483、アトピー性皮膚炎を対象とした第I相臨床試験中のNM26-2198、末梢神経障害性疼痛を対象とした第I相臨床試験中のKP-910、先天性副腎過形成を対象とした第I相臨床試験中のTildacerfontなどがある。さらに、文京グリーンコートの賃貸にも携わっている。同社は、皮膚科を適応症とする選択的経口チロシンキナーゼ2（TYK2）阻害剤ESK-001を日本で開発、製造、商業化するための提携およびライセンス契約を株式会社アルミスと結んでいる。科研製薬株式会社は1917年に設立され、東京に本社を置いている。もっと見るKaken Pharmaceutical Co., Ltd. 基礎のまとめKaken Pharmaceutical の収益と売上を時価総額と比較するとどうか。4521 基礎統計学時価総額JP¥152.61b収益（TTM）JP¥10.31b売上高(TTM)JP¥88.16b14.8xPER（株価収益率1.7xP/Sレシオ4521 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計4521 損益計算書（TTM）収益JP¥88.16b売上原価JP¥37.07b売上総利益JP¥51.09bその他の費用JP¥40.78b収益JP¥10.31b直近の収益報告Jun 30, 2026次回決算日該当なし一株当たり利益（EPS）272.31グロス・マージン57.95%純利益率11.70%有利子負債／自己資本比率2.5%4521 の長期的なパフォーマンスは？過去の実績と比較を見る配当金4.7%現在の配当利回り70%配当性向4521 配当は確実ですか？4521 配当履歴とベンチマークを見る4521 、いつまでに購入すれば配当金を受け取れますか？Kaken Pharmaceutical 配当日配当落ち日Sep 29 2026配当支払日Nov 30 2026配当落ちまでの日数41 days配当支払日までの日数103 days4521 配当は確実ですか？4521 配当履歴とベンチマークを見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/18 10:30終値2026/08/18 00:00収益2026/06/30年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Kaken Pharmaceutical Co., Ltd. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Kazuaki HashiguchiDaiwa Securities Co. Ltd.Junya YamazakiJefferies LLCToshiyuki IwataMizuho Securities Co., Ltd.6 その他のアナリストを表示
Reported Earnings • Aug 08First quarter 2027 earnings released: EPS: JP¥223 (vs JP¥7.12 in 1Q 2026)First quarter 2027 results: EPS: JP¥223 (up from JP¥7.12 in 1Q 2026). Revenue: JP¥30.2b (up 60% from 1Q 2026). Net income: JP¥8.44b (up JP¥8.17b from 1Q 2026). Profit margin: 28% (up from 1.4% in 1Q 2026). Revenue is expected to decline by 1.2% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 3.4%. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
Declared Dividend • Jul 25Final dividend of JP¥95.00 announcedShareholders will receive a dividend of JP¥95.00. Ex-date: 29th September 2026 Payment date: 30th November 2026 Dividend yield will be 4.9%, which is higher than the industry average of 2.3%. Sustainability & Growth Dividend is not covered by earnings (336% earnings payout ratio) and the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 3.4% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 273% to bring the payout ratio under control. EPS is expected to grow by 33% over the next 3 years, which means the dividend may need to be reduced to reach a sustainable payout ratio.
Major Estimate Revision • Jul 22Consensus EPS estimates increase by 44%The consensus outlook for earnings per share (EPS) in fiscal year 2027 has improved. 2027 revenue forecast increased from JP¥79.6b to JP¥82.8b. EPS estimate increased from JP¥85.09 to JP¥122 per share. Net income forecast to grow 116% next year vs 3.4% growth forecast for Pharmaceuticals industry in Japan. Consensus price target up from JP¥4,350 to JP¥4,500. Share price was steady at JP¥3,890 over the past week.
Buy Or Sell Opportunity • Jun 26Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to JP¥3,815. The fair value is estimated to be JP¥4,804, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Earnings per share has declined by 6.4%. For the next 3 years, revenue is forecast to grow by 2.2% per annum. Earnings are also forecast to grow by 15% per annum over the same time period.
Major Estimate Revision • Jun 17Consensus EPS estimates increase by 54%The consensus outlook for earnings per share (EPS) in fiscal year 2027 has improved. 2027 revenue forecast increased from JP¥76.5b to JP¥79.6b. EPS estimate increased from JP¥55.42 to JP¥85.09 per share. Net income forecast to grow 50% next year vs 3.3% growth forecast for Pharmaceuticals industry in Japan. Consensus price target broadly unchanged at JP¥4,350. Share price was steady at JP¥3,830 over the past week.
Buy Or Sell Opportunity • Jun 02Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to JP¥3,790. The fair value is estimated to be JP¥4,804, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Earnings per share has declined by 6.4%. For the next 3 years, revenue is forecast to grow by 2.4% per annum. Earnings are also forecast to grow by 20% per annum over the same time period.
Reported Earnings • Aug 08First quarter 2027 earnings released: EPS: JP¥223 (vs JP¥7.12 in 1Q 2026)First quarter 2027 results: EPS: JP¥223 (up from JP¥7.12 in 1Q 2026). Revenue: JP¥30.2b (up 60% from 1Q 2026). Net income: JP¥8.44b (up JP¥8.17b from 1Q 2026). Profit margin: 28% (up from 1.4% in 1Q 2026). Revenue is expected to decline by 1.2% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 3.4%. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
Declared Dividend • Jul 25Final dividend of JP¥95.00 announcedShareholders will receive a dividend of JP¥95.00. Ex-date: 29th September 2026 Payment date: 30th November 2026 Dividend yield will be 4.9%, which is higher than the industry average of 2.3%. Sustainability & Growth Dividend is not covered by earnings (336% earnings payout ratio) and the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 3.4% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 273% to bring the payout ratio under control. EPS is expected to grow by 33% over the next 3 years, which means the dividend may need to be reduced to reach a sustainable payout ratio.
Major Estimate Revision • Jul 22Consensus EPS estimates increase by 44%The consensus outlook for earnings per share (EPS) in fiscal year 2027 has improved. 2027 revenue forecast increased from JP¥79.6b to JP¥82.8b. EPS estimate increased from JP¥85.09 to JP¥122 per share. Net income forecast to grow 116% next year vs 3.4% growth forecast for Pharmaceuticals industry in Japan. Consensus price target up from JP¥4,350 to JP¥4,500. Share price was steady at JP¥3,890 over the past week.
Buy Or Sell Opportunity • Jun 26Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to JP¥3,815. The fair value is estimated to be JP¥4,804, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Earnings per share has declined by 6.4%. For the next 3 years, revenue is forecast to grow by 2.2% per annum. Earnings are also forecast to grow by 15% per annum over the same time period.
Major Estimate Revision • Jun 17Consensus EPS estimates increase by 54%The consensus outlook for earnings per share (EPS) in fiscal year 2027 has improved. 2027 revenue forecast increased from JP¥76.5b to JP¥79.6b. EPS estimate increased from JP¥55.42 to JP¥85.09 per share. Net income forecast to grow 50% next year vs 3.3% growth forecast for Pharmaceuticals industry in Japan. Consensus price target broadly unchanged at JP¥4,350. Share price was steady at JP¥3,830 over the past week.
Buy Or Sell Opportunity • Jun 02Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to JP¥3,790. The fair value is estimated to be JP¥4,804, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Earnings per share has declined by 6.4%. For the next 3 years, revenue is forecast to grow by 2.4% per annum. Earnings are also forecast to grow by 20% per annum over the same time period.
お知らせ • May 30Kaken Pharmaceutical Co., Ltd. to Report Q1, 2027 Results on Aug 07, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2027 results on Aug 07, 2026
分析記事 • May 20Why Kaken Pharmaceutical's (TSE:4521) Shaky Earnings Are Just The Beginning Of Its ProblemsKaken Pharmaceutical Co., Ltd.'s ( TSE:4521 ) recent weak earnings report didn't cause a big stock movement. We think...
Reported Earnings • May 15Full year 2026 earnings: EPS in line with analyst expectations despite revenue beatFull year 2026 results: EPS: JP¥56.55 (down from JP¥365 in FY 2025). Revenue: JP¥76.9b (down 18% from FY 2025). Net income: JP¥2.14b (down 85% from FY 2025). Profit margin: 2.8% (down from 15% in FY 2025). Revenue exceeded analyst estimates by 5.5%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
お知らせ • May 13Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2026Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2026.
お知らせ • Apr 01Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 13, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 13, 2026
Upcoming Dividend • Mar 23Upcoming dividend of JP¥95.00 per shareEligible shareholders must have bought the stock before 30 March 2026. Payment date: 30 June 2026. The company is not currently making a profit and is not cash flow positive. Trailing yield: 4.6%. Within top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (2.4%).
Reported Earnings • Feb 07Third quarter 2026 earnings: EPS and revenues miss analyst expectationsThird quarter 2026 results: EPS: JP¥10.72 (down from JP¥129 in 3Q 2025). Revenue: JP¥18.3b (down 26% from 3Q 2025). Net income: JP¥406.0m (down 92% from 3Q 2025). Profit margin: 2.2% (down from 20% in 3Q 2025). Revenue missed analyst estimates by 5.7%. Earnings per share (EPS) also missed analyst estimates by 57%. Revenue is expected to decline by 2.0% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 3.9%. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 5% per year.
分析記事 • Dec 19Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥95.00Kaken Pharmaceutical Co., Ltd.'s ( TSE:4521 ) investors are due to receive a payment of ¥95.00 per share on 30th of...
お知らせ • Dec 19Kaken Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 06, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026
分析記事 • Nov 29Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥95.00Kaken Pharmaceutical Co., Ltd. ( TSE:4521 ) will pay a dividend of ¥95.00 on the 30th of June. This takes the dividend...
Declared Dividend • Nov 29First half dividend of JP¥95.00 announcedShareholders will receive a dividend of JP¥95.00. Ex-date: 30th March 2026 Payment date: 30th June 2026 Dividend yield will be 4.9%, which is higher than the industry average of 2.3%. Sustainability & Growth Dividend is not covered by earnings (440% earnings payout ratio) and the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 5.8% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 389% to bring the payout ratio under control. EPS is expected to grow by 34% over the next 3 years, which means the dividend may need to be reduced to reach a sustainable payout ratio.
分析記事 • Nov 18We Think You Can Look Beyond Kaken Pharmaceutical's (TSE:4521) Lackluster EarningsShareholders appeared unconcerned with Kaken Pharmaceutical Co., Ltd.'s ( TSE:4521 ) lackluster earnings report last...
Reported Earnings • Nov 12Second quarter 2026 earnings released: EPS: JP¥19.04 (vs JP¥331 in 2Q 2025)Second quarter 2026 results: EPS: JP¥19.04 (down from JP¥331 in 2Q 2025). Revenue: JP¥20.5b (down 38% from 2Q 2025). Net income: JP¥721.0m (down 94% from 2Q 2025). Profit margin: 3.5% (down from 38% in 2Q 2025). Revenue is expected to decline by 3.6% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 3.8%. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
お知らせ • Sep 29Kaken Pharmaceutical Co., Ltd. Revises Consolidated Financial Forecast for Fiscal Year Ending March 31, 2026Kaken Pharmaceutical Co., Ltd. revised consolidated financial forecast for fiscal year ending March 31, 2026. For the period, the company expects net sales of JPY 86,300 million compared to previous guidance of JPY 88,000 million, operating profit of JPY 2,100 million compared to previous guidance of JPY 5,200 million and profit attributable to owners of parent company of JPY 2,300 compared to previous guidance of JPY 3,400 million or basic earnings per share of JPY 60.74 per share compared to previous guidance of JPY 88.53.
Upcoming Dividend • Sep 22Upcoming dividend of JP¥95.00 per shareEligible shareholders must have bought the stock before 29 September 2025. Payment date: 01 December 2025. Payout ratio is a comfortable 46% and this is well supported by cash flows. Trailing yield: 4.9%. Within top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (2.7%).
お知らせ • Sep 11Kaken Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 10, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 10, 2025
Reported Earnings • Aug 08First quarter 2026 earnings released: EPS: JP¥7.12 (vs JP¥46.32 in 1Q 2025)First quarter 2026 results: EPS: JP¥7.12 (down from JP¥46.32 in 1Q 2025). Revenue: JP¥18.9b (up 3.4% from 1Q 2025). Net income: JP¥271.0m (down 85% from 1Q 2025). Profit margin: 1.4% (down from 9.6% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is expected to decline by 6.3% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 3.9%. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Declared Dividend • Jul 09Final dividend of JP¥95.00 announcedShareholders will receive a dividend of JP¥95.00. Ex-date: 29th September 2025 Payment date: 1st December 2025 Dividend yield will be 4.5%, which is higher than the industry average of 2.3%. Sustainability & Growth Dividend is well covered by both earnings (28% earnings payout ratio) and cash flows (28% cash payout ratio). The dividend has increased by an average of 5.8% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to decline by 83% over the next 3 years. Since a fall of 69% would increase the payout ratio to a potentially unsustainable range, the dividend may be at risk.
お知らせ • May 31Kaken Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025
Major Estimate Revision • May 29Consensus revenue estimates increase by 19%, EPS downgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from JP¥74.2b to JP¥88.3b. EPS estimate fell from JP¥128 to JP¥80.45. Net income forecast to shrink 78% next year vs 0.2% growth forecast for Pharmaceuticals industry in Japan . Consensus price target down from JP¥4,850 to JP¥4,600. Share price rose 2.0% to JP¥3,813 over the past week.
分析記事 • May 19We Think Kaken Pharmaceutical's (TSE:4521) Robust Earnings Are ConservativeInvestors were underwhelmed by the solid earnings posted by Kaken Pharmaceutical Co., Ltd. ( TSE:4521 ) recently. We...
Reported Earnings • May 13Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: EPS: JP¥365 (up from JP¥213 in FY 2024). Revenue: JP¥94.0b (up 31% from FY 2024). Net income: JP¥13.9b (up 74% from FY 2024). Profit margin: 15% (up from 11% in FY 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 3.8%. Earnings per share (EPS) missed analyst estimates by 6.5%. Revenue is expected to decline by 8.0% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 3.6%. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
分析記事 • May 12We Think Kaken Pharmaceutical (TSE:4521) Can Manage Its Debt With EaseWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
お知らせ • May 12+ 3 more updatesKaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2025Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2025.
分析記事 • Apr 15There's Reason For Concern Over Kaken Pharmaceutical Co., Ltd.'s (TSE:4521) PriceWith a median price-to-sales (or "P/S") ratio of close to 1.5x in the Pharmaceuticals industry in Japan, you could be...
お知らせ • Apr 11Kaken Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecast for Fiscal Year Ended March 31, 2025Kaken Pharmaceutical Co., Ltd. revised consolidated earnings forecast for fiscal year ended March 31, 2025. For the year, the company expected net sales of JPY 94,000 million compared to previous forecast of JPY 88,500 million; Operating profit of JPY 20,800 million compared to previous forecast of JPY 20,800 million; Profit attributable to owners of the parent of JPY 14,000 million compared to previous forecast of JPY 14,200 million and Basic earnings per share of JPY 364.55 compared to previous forecast of JPY 374.97. The forecast for net sales has been revised upward from the previously announced forecast to reflect the receipt of an upfront payment as described in the press release KAKEN Entered into a License Agreement for STAT6 Inhibitor announced on December 26, 2024, and other factors. Operating profit, ordinary profit, and profit attributable to owners of the parent have been partially revised to reflect the upfront payment as described in the press release Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan announced on March 25, 2025, as well as the expenses described in the press release Notice of Completion of Acquisition of Aadi Subsidiaries, Inc, U.S.A. announced on March 27, 2025.
分析記事 • Mar 27Kaken Pharmaceutical (TSE:4521) Is Due To Pay A Dividend Of ¥75.00Kaken Pharmaceutical Co., Ltd. ( TSE:4521 ) will pay a dividend of ¥75.00 on the 30th of June. This means the annual...
お知らせ • Mar 26Kaken Pharmaceutical Co., Ltd. (TSE:4521) completed the acquisition of Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $102.4 million.Kaken Pharmaceutical Co., Ltd. (TSE:4521) entered into a stock purchase agreement to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million on December 19, 2024. The purchase price is subject to customary adjustments. The board of directors of Aadi approved and recommend that Aadi’s stockholders vote in favor of, and authorize the approval of, the purchase agreement and stock purchase. Completion of the stock purchase is subject to customary closing conditions, including all consents and approvals required under certain regulatory laws having been obtained and the absence of any law or order preventing, materially restraining or materially impairing the consummation of the stock purchase. Completion of the Stock Purchase is also subject, with certain exception, to the completion of certain internal pre-closing restructuring transaction. In case of termination of transaction, Aadi Bioscience, Inc. will pay a termination fee of $3.50 million. The transaction is expected to close in the first half of 2025. On February 28, 2025, shareholders of Aadi Bioscience approved the transaction. Matt Carter and David A. Lipkin of McDermott Will & Emery LLP acted as legal advisor to Kaken Pharmaceutical Co., Ltd. Dan Koeppen, Robert L. Wernli, Jr., Ethan Lutske and Jack Hamilton of Wilson Sonsini Goodrich & Rosati acted as legal advisor and Leerink Partners LLC acted as Financial advisor to Aadi Bioscience, Inc. Kaken Pharmaceutical Co., Ltd. (TSE:4521) completed the acquisition of Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $102.4 million on March 25, 2025.
お知らせ • Mar 25Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 12, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 12, 2025
Upcoming Dividend • Mar 21Upcoming dividend of JP¥75.00 per shareEligible shareholders must have bought the stock before 28 March 2025. Payment date: 30 June 2025. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 3.2%. Lower than top quartile of Japanese dividend payers (3.7%). Higher than average of industry peers (2.6%).
分析記事 • Mar 13Kaken Pharmaceutical (TSE:4521) Will Pay A Dividend Of ¥75.00Kaken Pharmaceutical Co., Ltd. ( TSE:4521 ) has announced that it will pay a dividend of ¥75.00 per share on the 30th...
分析記事 • Feb 27Kaken Pharmaceutical (TSE:4521) Has Affirmed Its Dividend Of ¥75.00Kaken Pharmaceutical Co., Ltd. ( TSE:4521 ) has announced that it will pay a dividend of ¥75.00 per share on the 30th...
お知らせ • Feb 26Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces an Equity Buyback for 1,800,000 shares, representing 4.53% for ¥9,000 million.Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces a share repurchase program. Under the program, the company will repurchase 1,800,000 shares, representing 4.53% of its share capital, for ¥9,000 million. The purpose of the program is to strengthen shareholder returns and improve capital efficiency, as well as to address the dilution of shares resulting from the disposal of treasury stock. The program will run until September 30, 2025. As of January 31, 2025, the company had 39,758,792 shares in issue (excluding treasury stock) and 6,180,938 shares of treasury stock.
分析記事 • Feb 10Kaken Pharmaceutical (TSE:4521) Is Due To Pay A Dividend Of ¥75.00The board of Kaken Pharmaceutical Co., Ltd. ( TSE:4521 ) has announced that it will pay a dividend on the 30th of June...
Reported Earnings • Feb 07Third quarter 2025 earnings released: EPS: JP¥129 (vs JP¥68.84 in 3Q 2024)Third quarter 2025 results: EPS: JP¥129 (up from JP¥68.84 in 3Q 2024). Revenue: JP¥24.6b (up 33% from 3Q 2024). Net income: JP¥4.89b (up 88% from 3Q 2024). Profit margin: 20% (up from 14% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is expected to decline by 10% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 4.2%. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
分析記事 • Jan 10Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00Kaken Pharmaceutical Co., Ltd. ( TSE:4521 ) will pay a dividend of ¥75.00 on the 30th of June. The dividend yield will...
お知らせ • Dec 22Kaken Pharmaceutical Co., Ltd. (TSE:4521) agreed to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million.Kaken Pharmaceutical Co., Ltd. (TSE:4521) agreed to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million on December 19, 2024. Completion of the Stock Purchase is subject to customary closing conditions, including the approval of the Purchase Agreement and the Stock Purchase by the holders of a majority of the outstanding shares of Aadi’s capital stock entitled to vote to approve the Purchase Agreement and Stock Purchase, all consents and approvals required under certain regulatory laws having been obtained and the absence of any law or order preventing, materially restraining or materially impairing the consummation of the Stock Purchase. Completion of the Stock Purchase is also subject, with certain exception, to the completion of certain internal pre-closing restructuring transaction. In case of termination of transaction, Aadi Bioscience, Inc. will pay a termination fee of $3.50 million. The transaction is expected to close in the first half of 2025. Matt Carter and David A. Lipkin of McDermott Will & Emery LLP acted as legal advisor to Kaken Pharmaceutical Co., Ltd. Dan Koeppen, Robert L. Wernli, Jr., Ethan Lutske and Jack Hamilton of Wilson Sonsini Goodrich & Rosati acted as legal advisor to
分析記事 • Dec 20Kaken Pharmaceutical (TSE:4521) Has Announced A Dividend Of ¥75.00The board of Kaken Pharmaceutical Co., Ltd. ( TSE:4521 ) has announced that it will pay a dividend of ¥75.00 per share...
分析記事 • Dec 02Kaken Pharmaceutical (TSE:4521) Will Pay A Dividend Of ¥75.00Kaken Pharmaceutical Co., Ltd.'s ( TSE:4521 ) investors are due to receive a payment of ¥75.00 per share on 30th of...
Declared Dividend • Nov 30First half dividend of JP¥75.00 announcedShareholders will receive a dividend of JP¥75.00. Ex-date: 28th March 2025 Payment date: 30th June 2025 Dividend yield will be 4.4%, which is higher than the industry average of 2.3%. Sustainability & Growth Dividend is well covered by both earnings (31% earnings payout ratio) and cash flows (24% cash payout ratio). The dividend has increased by an average of 4.6% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to decline by 92% over the next 3 years. Since a fall of 65% would increase the payout ratio to a potentially unsustainable range, the dividend may be at risk.
お知らせ • Nov 30Kaken Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 06, 2025
Major Estimate Revision • Nov 15Consensus EPS estimates increase by 10%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from JP¥83.1b to JP¥87.8b. EPS estimate increased from JP¥354 to JP¥391 per share. Net income forecast to shrink 50% next year vs 0.4% decline forecast for Pharmaceuticals industry in Japan. Consensus price target of JP¥3,600 unchanged from last update. Share price rose 13% to JP¥4,369 over the past week.
Reported Earnings • Nov 09Second quarter 2025 earnings released: EPS: JP¥331 (vs JP¥41.29 in 2Q 2024)Second quarter 2025 results: EPS: JP¥331 (up from JP¥41.29 in 2Q 2024). Revenue: JP¥33.1b (up 84% from 2Q 2024). Net income: JP¥12.5b (up JP¥11.0b from 2Q 2024). Profit margin: 38% (up from 8.6% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is expected to decline by 8.9% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 4.5%. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 3% per year.
Upcoming Dividend • Sep 20Upcoming dividend of JP¥115 per shareEligible shareholders must have bought the stock before 27 September 2024. Payment date: 02 December 2024. Payout ratio is on the higher end at 78%, and the cash payout ratio is above 100%. Trailing yield: 3.8%. Within top quartile of Japanese dividend payers (3.8%). Higher than average of industry peers (2.3%).
お知らせ • Sep 03Kaken Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 08, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 08, 2024
分析記事 • Aug 13Estimating The Intrinsic Value Of Kaken Pharmaceutical Co., Ltd. (TSE:4521)Key Insights Using the Dividend Discount Model, Kaken Pharmaceutical fair value estimate is JP¥3,765 Current share...
分析記事 • Jul 26Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00Kaken Pharmaceutical Co., Ltd. ( TSE:4521 ) will pay a dividend of ¥75.00 on the 2nd of December. This makes the...
Major Estimate Revision • Jul 12Consensus revenue estimates increase by 18%The consensus outlook for revenues in fiscal year 2025 has improved. 2025 revenue forecast increased from JP¥70.2b to JP¥83.1b. EPS estimate increased from JP¥172 to JP¥354 per share. Net income forecast to grow 67% next year vs 0.1% decline forecast for Pharmaceuticals industry in Japan. Consensus price target up from JP¥3,500 to JP¥3,600. Share price rose 3.3% to JP¥4,058 over the past week.
分析記事 • Jul 11Kaken Pharmaceutical (TSE:4521) Has Announced A Dividend Of ¥75.00Kaken Pharmaceutical Co., Ltd. ( TSE:4521 ) will pay a dividend of ¥75.00 on the 2nd of December. This makes the...
Buy Or Sell Opportunity • Jul 11Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 17% to JP¥4,012. The fair value is estimated to be JP¥3,330, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 37%. For the next 3 years, revenue is forecast to decline by 6.5% per annum. Earnings are also forecast to decline by 48% per annum over the same time period.
お知らせ • Jun 26Kaken Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 07, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Aug 07, 2024
Reported Earnings • May 16Full year 2024 earnings: EPS exceeds analyst expectationsFull year 2024 results: EPS: JP¥213 (up from JP¥145 in FY 2023). Revenue: JP¥72.0b (down 1.3% from FY 2023). Net income: JP¥8.03b (up 48% from FY 2023). Profit margin: 11% (up from 7.5% in FY 2023). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 7.5%. Revenue is expected to decline by 6.5% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 4.5%. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
お知らせ • May 16Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024.
Upcoming Dividend • Mar 21Upcoming dividend of JP¥75.00 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 01 July 2024. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 4.2%. Within top quartile of Japanese dividend payers (3.2%). Higher than average of industry peers (2.3%).
分析記事 • Mar 04Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00Kaken Pharmaceutical Co., Ltd. ( TSE:4521 ) will pay a dividend of ¥75.00 on the 1st of July. This means the annual...
お知らせ • Mar 03Kaken Pharmaceutical Co., Ltd. to Report Q4, 2024 Results on May 09, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q4, 2024 results on May 09, 2024
Reported Earnings • Feb 08Third quarter 2024 earnings released: EPS: JP¥68.84 (vs JP¥85.00 in 3Q 2023)Third quarter 2024 results: EPS: JP¥68.84 (down from JP¥85.00 in 3Q 2023). Revenue: JP¥18.5b (down 1.3% from 3Q 2023). Net income: JP¥2.61b (down 18% from 3Q 2023). Profit margin: 14% (down from 17% in 3Q 2023). Revenue is expected to decline by 6.1% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 4.6%. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
お知らせ • Dec 08Kaken Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 06, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Feb 06, 2024
お知らせ • Nov 15+ 1 more updateKaken Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for Fiscal Year Ending March 31, 2024Kaken Pharmaceutical Co., Ltd. provided consolidated financial forecast for fiscal year ending March 31, 2024. For the year, the company expects net sales of ¥73,100 million, operating profit of ¥7,600 million, profit attributable to owners of the company of ¥6,700 million and basic earnings per share of ¥176.92.
Reported Earnings • Nov 10Second quarter 2024 earnings released: EPS: JP¥41.28 (vs JP¥81.46 in 2Q 2023)Second quarter 2024 results: EPS: JP¥41.28 (down from JP¥81.46 in 2Q 2023). Revenue: JP¥18.0b (down 3.2% from 2Q 2023). Net income: JP¥1.56b (down 49% from 2Q 2023). Profit margin: 8.6% (down from 16% in 2Q 2023). Revenue is expected to decline by 5.9% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 3.5%. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Sep 21Upcoming dividend of JP¥75.00 per share at 4.2% yieldEligible shareholders must have bought the stock before 28 September 2023. Payment date: 30 November 2023. The company is paying out more than 100% of its profits and is paying out 80% of its cash flow. Trailing yield: 4.2%. Within top quartile of Japanese dividend payers (3.3%). Higher than average of industry peers (2.2%).
お知らせ • Sep 19Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index (USD)Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index (USD)
お知らせ • Aug 30Kaken Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 08, 2023Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2024 results on Nov 08, 2023
お知らせ • Aug 18+ 1 more updateKaken Pharmaceutical Co., Ltd. Provides Dividend Forecast for Second Quarter of 2024 and Fiscal Year Ending March 31, 2024Kaken Pharmaceutical Co., Ltd. provided dividend forecast for second quarter of 2024 and fiscal year ending March 31, 2024. For the quarter, the company expects to pay a dividend of ¥75 against ¥75 paid last year.For the year, the company expects to pay a dividend of ¥75 against ¥75 paid last year.
Reported Earnings • Aug 09First quarter 2024 earnings released: EPS: JP¥66.98 (vs JP¥76.89 in 1Q 2023)First quarter 2024 results: EPS: JP¥66.98 (down from JP¥76.89 in 1Q 2023). Revenue: JP¥18.2b (flat on 1Q 2023). Net income: JP¥2.51b (down 14% from 1Q 2023). Profit margin: 14% (down from 16% in 1Q 2023). Revenue is expected to decline by 5.7% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 3.9%. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.
New Risk • Jul 16New minor risk - Dividend sustainabilityThe dividend is not well covered by earnings. Payout ratio: 104% Dividend yield: 4.3% This is considered a minor risk. Companies that pay out too much of their earnings are at risk of having to reduce or cut their dividend in future. If earnings growth slows or earnings fall, then there may not be enough earnings to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. However, this risk is mitigated by the fact the dividend is covered by cash flows. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 30% per year for the foreseeable future. Minor Risks Dividend is not well covered by earnings (104% payout ratio). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (7.5% net profit margin).
Major Estimate Revision • Jun 03Consensus EPS estimates fall by 26%, revenue upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from JP¥69.6b to JP¥72.7b. EPS estimate fell from JP¥267 to JP¥198 per share. Net income forecast to grow 40% next year vs 9.7% growth forecast for Pharmaceuticals industry in Japan. Consensus price target up from JP¥3,200 to JP¥3,500. Share price was steady at JP¥3,585 over the past week.
お知らせ • May 28Kaken Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 04, 2023Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Aug 04, 2023
お知らせ • May 12Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023.
Reported Earnings • May 12Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2023 results: EPS: JP¥145 (down from JP¥251 in FY 2022). Revenue: JP¥73.0b (down 4.0% from FY 2022). Net income: JP¥5.44b (down 43% from FY 2022). Profit margin: 7.5% (down from 13% in FY 2022). Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) missed analyst estimates by 50%. Revenue is expected to decline by 6.5% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 4.6%. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Mar 23Upcoming dividend of JP¥75.00 per share at 4.1% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 30 June 2023. Payout ratio is a comfortable 67% and this is well supported by cash flows. Trailing yield: 4.1%. Within top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (2.3%).
Reported Earnings • Feb 04Third quarter 2023 earnings released: EPS: JP¥84.99 (vs JP¥93.21 in 3Q 2022)Third quarter 2023 results: EPS: JP¥84.99 (down from JP¥93.21 in 3Q 2022). Revenue: JP¥18.8b (down 6.8% from 3Q 2022). Net income: JP¥3.19b (down 9.6% from 3Q 2022). Profit margin: 17% (in line with 3Q 2022). Revenue is expected to decline by 6.0% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 4.8%. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.
お知らせ • Dec 28Kaken Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 03, 2023Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Feb 03, 2023
Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: JP¥81.46 (vs JP¥88.47 in 2Q 2022)Second quarter 2023 results: EPS: JP¥81.46 (down from JP¥88.47 in 2Q 2022). Revenue: JP¥18.6b (down 2.7% from 2Q 2022). Net income: JP¥3.06b (down 9.0% from 2Q 2022). Profit margin: 16% (down from 18% in 2Q 2022). Revenue is expected to decline by 6.0% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 4.5%. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 2 independent directors. 7 non-independent directors. Independent Outside Director Shoichiro Takagi was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Reported Earnings • Nov 10Second quarter 2023 earnings released: EPS: JP¥81.46 (vs JP¥88.47 in 2Q 2022)Second quarter 2023 results: EPS: JP¥81.46 (down from JP¥88.47 in 2Q 2022). Revenue: JP¥18.6b (down 2.7% from 2Q 2022). Net income: JP¥3.06b (down 9.0% from 2Q 2022). Profit margin: 16% (down from 18% in 2Q 2022). Revenue is expected to decline by 6.0% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 4.6%. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Sep 22Upcoming dividend of JP¥75.00 per shareEligible shareholders must have bought the stock before 29 September 2022. Payment date: 30 November 2022. Payout ratio is a comfortable 62% and this is well supported by cash flows. Trailing yield: 4.0%. Within top quartile of Japanese dividend payers (3.7%). Higher than average of industry peers (2.3%).
お知らせ • Aug 28Kaken Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Nov 08, 2022Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2023 results on Nov 08, 2022
Reported Earnings • Aug 04First quarter 2023 earnings released: EPS: JP¥76.89 (vs JP¥87.76 in 1Q 2022)First quarter 2023 results: EPS: JP¥76.89 (down from JP¥87.76 in 1Q 2022). Revenue: JP¥18.2b (down 1.4% from 1Q 2022). Net income: JP¥2.91b (down 14% from 1Q 2022). Profit margin: 16% (down from 18% in 1Q 2022). Over the next year, revenue is expected to shrink by 6.3% compared to a 4.7% growth forecast for the industry in Japan. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
お知らせ • Jun 03Kaken Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 03, 2022Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2023 results on Aug 03, 2022
お知らせ • May 26+ 1 more updateKaken Pharmaceutical Co., Ltd. Announces Year-End Dividend for the Fiscal Year Ended March 31, 2022, Payable on June 30, 2022; Provides Second Quarter and Fiscal Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2023Kaken Pharmaceutical Co., Ltd. announced year end dividend of JPY 75 per share for the fiscal year ended March 31, 2022, payable on June 30, 2022, compared to JPY 75 per share paid an year ago.Kaken Pharmaceutical Co., Ltd. provided second quarter and fiscal year ending March 31, 2023 dividend guidance of JPY 75 per share each, compared to JPY 75 per share paid during fiscal year ended March 31, 2022.
Reported Earnings • May 13Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: EPS: JP¥251 (down from JP¥347 in FY 2021). Revenue: JP¥76.0b (up 1.4% from FY 2021). Net income: JP¥9.55b (down 29% from FY 2021). Profit margin: 13% (down from 18% in FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.4%. Over the next year, revenue is expected to shrink by 6.6% compared to a 4.6% growth forecast for the pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
お知らせ • May 13Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2022Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2022.
お知らせ • May 12Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces an Equity Buyback for 350,000 shares, representing 0.92% for ¥1,500 million.Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces a share repurchase program. Under the program, the company will repurchase 350,000 shares, representing 0.92% of its share capital, for ¥1,500 million. The purpose of the program is to implement a flexible capital policy in response to changes in the business environment. The program will run until December 28, 2022. As of April 30, 2022, the company had 37,856,819 shares in issue (excluding treasury stock) and 8,082,911 shares of treasury stock.
